Seminars in thrombosis and hemostasis最新文献

{"title":"Large Language Models for Viscoelastic Tests: A Head-to-Head Evaluation of ChatGPT, Gemini, and DeepSeek for Thromboelastography and ROTEM Interpretation.","authors":"Jun Kai Yeong, Mauro Panigada, Mohammad Ahmad Altememi, Emmanuel J Favaloro, Bingwen Eugene Fan","doi":"10.1055/a-2918-4009","DOIUrl":"10.1055/a-2918-4009","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148607245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Correspondence: \"Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses\".","authors":"Valérie Horvais, Catherine Ternisien, Julien Denis Le Sève, Philippe Beurrier, Marc Fouassier, Antoine Babuty, Nicolas Drillaud, Brigitte Pan-Petesch, Johann Rose, Vincent Cussac, Sophie Bayart, Benoit Guillet, Marc Trossaërt","doi":"10.1055/a-2913-6907","DOIUrl":"10.1055/a-2913-6907","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Count-Guided Low Molecular Weight Heparin Management of Catheter-Related Thrombosis in a Large Cohort of Patients with Newly Diagnosed Acute Leukemia.","authors":"Shay Perek, Niv Izhaki, Ron Hoffman, Benjamin Brenner, Netanel A Horowitz","doi":"10.1055/a-2905-4225","DOIUrl":"10.1055/a-2905-4225","url":null,"abstract":"<p><strong>Abstract: </strong>Treatment of catheter-related thrombosis (CRT) in acute leukemia patients is challenging due to concomitant thrombocytopenia. Although modified-dose anticoagulation is frequently used in this setting, several vital outcomes remain unclear. The current study evaluated clinical outcomes of a platelet-count-guided low molecular weight heparin (LMWH) regimen in these patients. Data on all newly diagnosed acute leukemia patients, who developed CRT, were retrieved from the institutional database. Upon CRT diagnosis, patients received either a full or modified dose of LMWH, based on their platelet counts. Outcomes included recurrent venous thromboembolism (VTE), hemorrhagic events. Competing risk analyses were performed, with death considered a competing risk. All-cause mortality and blood product utilization (per patient; pre- and postanticoagulation commencement) were compared. A total of 193 acute leukemia patients diagnosed with CRT between November 2004 and May 2022 were included. Eighty-seven patients (45%) received full-dose LMWH. Modified-dose LMWH treatment was associated with hazard ratio (HR) of 0.642 (95% confidence interval [CI]: 0.268-1.540; <i>p</i> = 0.320) in terms of CRT recurrence and HR of 0.975 (95% CI: 0.439-2.170; <i>p</i> = 0.950) in terms of hemorrhage. Mortality was not significantly higher in the modified-dose group (HR: 1.47, 95% CI: 0.93-2.32; <i>p</i> = 0.092). Notably, platelet requirement did not differ before and after the CRT diagnosis, irrespective of LMWH doses used (full-dose group: median pre-CRT 0.09 [interquartile range, IQR: 0-0.27] vs. post-CRT 0.05 [IQR: 0.01-0.14] units/day, <i>p</i> = 0.059; modified-dose group: median pre-CRT 0.03 [IQR: 0-0.24] vs. post-CRT 0.07 [IQR: 0.01-0.18] units/day, <i>p</i> = 0.720). In acute leukemia patients with CRT, a platelet-count-guided LMWH regimen was not associated with higher rates of recurrent VTE, hemorrhagic complications, mortality, or platelet transfusion requirements.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seminars in Thrombosis and Hemostasis: 2025 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics.","authors":"Emmanuel J Favaloro","doi":"10.1055/a-2910-6717","DOIUrl":"https://doi.org/10.1055/a-2910-6717","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelets in Children: Physiological Function, Developmental Regulation, and Clinical Significance in Disease States.","authors":"Natasha Letunica, Paul Monagle, Chantal Attard","doi":"10.1055/a-2907-8906","DOIUrl":"10.1055/a-2907-8906","url":null,"abstract":"<p><strong>Abstract: </strong>Platelets play a fundamental role in hemostasis; however, their phenotype, reactivity, and function vary across the pediatric age spectrum. While developmental differences in plasma coagulation proteins have been well-characterized in children, differences in platelet biology remain poorly understood, with most studies focused on neonates. Consequently, the understanding of normal platelet phenotype and function in healthy children remains limited, making it difficult to interpret platelet changes in the context of disease. Platelet phenotype evolves from birth through adolescence, with ongoing changes in receptor expression and granule content. Functional responses also change with age, with neonatal platelets being hyporeactive compared with adult platelets, whereas platelets from older children may demonstrate increased responsiveness to common agonists. These developmental differences are increasingly recognized as clinically relevant across a range of pediatric disease states. However, key knowledge gaps remain in age-specific reference ranges and the translation of platelet biology into clinical practice. This review summarizes the current evidence on developmental differences in platelet production, phenotype, and reactivity from birth to adolescence and examines their clinical significance in pediatric disease states.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Evolution: Between Hemorrhage and Thrombosis.","authors":"Massimo Franchini, Matteo Zani, Daniele Focosi","doi":"10.1055/a-2905-4308","DOIUrl":"10.1055/a-2905-4308","url":null,"abstract":"<p><strong>Abstract: </strong>The human coagulation system has resulted from thousands of years of evolutionary pressure, finely balancing the competing risks of lethal hemorrhage and catastrophic thrombosis. There are several examples of the close interaction between the two opposing sides of hemostasis. A paradigmatic case is offered by the factor V Leiden mutation. Emerging approximately 22,000 years ago, this gain-of-function variant is now expressed in approximately 5% of Caucasians. While it now significantly elevates the risk of venous thromboembolism, it historically provided crucial evolutionary advantages, including reduced peripartum blood loss, enhanced iron stores, improved fertility, and increased embryo implantation rates. Conversely, congenital hypocoagulable states, such as hemophilia, demonstrate the other side of the coin. With modern therapeutic advances now extend the life expectancy of individuals with hemophilia, clinicians are increasingly managing age-related comorbidities. While experimental models suggest a chr onic hypocoagulable state might mitigate the risk of occlusive cardiovascular events or suppress cancer metastasis, clinical and epidemiological data remain conflicting. Mild factor deficiencies may offer some protection against ischemic heart disease, but overall cardiovascular and oncological risk profiles in patients with hemophilia increasingly mirror those of the aging general population. This review explores the genetic and environmental forces that shape this homeostatic equilibrium, illustrating how historical survival mechanisms influence modern disease patterns.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.","authors":"Paolo Santini, Davide Santagata, Carolina Mosoni, Francesco Mancinetti, Angelo Porfidia, Lorenza Bertù, Chiara Zurlo, Tatiana Scandiuzzi Piovesan, Danilo Menichelli, Pasquale Pignatelli, Adriana Visonà, Marco Paolo Donadini, Walter Ageno, Roberto Pola","doi":"10.1055/a-2904-5824","DOIUrl":"10.1055/a-2904-5824","url":null,"abstract":"<p><strong>Abstract: </strong>Extended anticoagulation is recommended in subjects with cancer-associated thrombosis (CT). The API-CT trial showed that reduced-dose apixaban is noninferior to full dose for preventing recurrent venous thromboembolism (VTE), but the generalizability of these findings to real-world populations remains to be determined. We conducted a multicenter retrospective cohort study including patients with CT receiving extended direct oral anticoagulants (DOACs) at full or reduced dose, after at least 6 months of anticoagulation. The primary efficacy outcome was recurrent VTE. The primary safety outcome was major bleeding (MB) and clinically relevant nonmajor bleeding (CRNMB). A total of 603 patients were included, of whom 381 (63.2%) received reduced-dose and 222 (36.8%) full-dose DOACs. During a median follow-up of 335 days, recurrent VTE occurred in 3.9% of patients in the reduced-dose and 2.7% in the full-dose group (<i>p</i> = 0.4). MB occurred in 1.0 and 0.9% (<i>p</i> = 0.9) and CRNMB in 4.7 and 5.4% (<i>p</i> = 0.7), respectively. In adjusted analyses, reduced-dose DOACs were associated with a nonsignificant increase in VTE recurrence (hazard ratio: 1.4, 95% confidence interval: 0.5-3.7), with no differences in bleeding outcomes. In this multicenter real-world cohort, reduced-dose DOACs were associated with low rates of recurrent VTE and bleeding, comparable to those observed with full-dose regimens. These findings suggest that reduced-dose anticoagulation may be a feasible option in selected patients with CT requiring extended treatment, supporting individualized decision-making. Further studies are needed to better define optimal dose selection in this setting.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large, Single-Center Retrospective Cohort Study.","authors":"Kristina M Wagner, Leslie J Raffini, Hilary B Whitworth","doi":"10.1055/a-2900-6956","DOIUrl":"10.1055/a-2900-6956","url":null,"abstract":"<p><strong>Abstract: </strong>Pediatric pulmonary embolism (PE) is a relatively rare but high-risk disease. There is minimal evidence to guide clinical management, particularly with respect to reperfusion therapies. Few studies capture bleeding outcomes to inform risk-benefit management decisions. In this single-center, retrospective cohort study, we aimed to describe pediatric patients <21 years of age who received acute PE care at our institution, excluding those with comorbid cardiac disease. We described the PE risk factors, in-hospital management, and acute outcomes, including bleeding and mortality. Between 2003 and 2022, 175 patients met eligibility: 120 low-risk (69%), 44 intermediate-risk (25%), and 11 high-risk (6%) PE. Most (<i>N</i> = 142) received anticoagulation alone; 29 patients received reperfusion therapy for PE, the most common reperfusion therapy was systemic thrombolysis. There were 34 clinically relevant bleeding events in 27 patients, including major bleeding in 9 (5%) and clinically relevant non-major bleeding events in 18 (10%) patients. Sixty-two percent (21/34) of bleeding events occurred in patients receiving anticoagulation alone, whereas 10/34 (29%) occurred in patients receiving systemic thrombolysis. In the high-risk PE cohort, clinically relevant bleeding occurred in 73% and 45% died. Most patients with major bleeding had other bleeding risk factors independent of their PE-directed therapy. All-cause mortality was 4%, with 2% PE-related mortality. This cohort study highlights that reperfusion therapy is well-tolerated in select pediatric patients and rates of bleeding and death are high in high-risk PE. Future research should validate these findings with prospective, standardized bleeding outcome collection to inform management decisions in pediatric PE.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148332470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut Microbiome-Associated Thrombosis: Approaching Validation?","authors":"Konstantina Tsante, Eleni Petrou, Stavros Tsalas, Andreas G Tsantes, Alexandra Lianou, Georgios Kartelias, Elias Kyriakou, Styliani Kokoris, Georgios Nikolopoulos, Stefanos Bonovas, Rozeta Sokou","doi":"10.1055/a-2900-7086","DOIUrl":"10.1055/a-2900-7086","url":null,"abstract":"<p><strong>Abstract: </strong>Gut microbiome has emerged as an important modulator of thrombotic disease through complex immunometabolic and interorgan pathways. Microbiome-derived metabolites have been associated with platelet activation, endothelial injury, and adverse cardiovascular outcomes. However, evidence remains stronger for arterial than for venous thrombosis, although accumulating data suggest that dysbiosis may represent an important yet underrecognized contributor to the pathogenesis of venous thromboembolism. While current evidence supports a biologically plausible association between the gut microbiome and thrombosis, further studies are needed to clarify the underlying mechanisms and determine their clinical significance.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red Blood Cell Biomechanics and Cancer-Associated Thrombosis.","authors":"George Ilbawi, Isabell Kearn, Maha Othman","doi":"10.1055/a-2875-0630","DOIUrl":"10.1055/a-2875-0630","url":null,"abstract":"<p><strong>Abstract: </strong>Cancer-associated thrombosis (CAT) remains a leading cause of morbidity and mortality in oncology, reflecting the convergence of tumor-driven hypercoagulability, endothelial dysfunction, and venous stasis. While current models of CAT pathogenesis emphasize tumor-derived procoagulant factors, platelets, and leukocytes, the contribution of red blood cell (RBC) biomechanics has received comparatively limited attention. Emerging evidence indicates that both malignancy and cancer-related therapies impair RBC deformability and increase RBC aggregation; alterations that are known to influence blood viscosity, platelet margination, microvascular flow, and clot contraction. Hence, these alterations have been hypothesized to promote thrombosis, supported by evidence of increased thrombosis risk in diseases that primarily affect RBC biomechanics. While cancer-induced alterations in RBC biomechanics and their role in thrombosis are well-described in non-cancerous conditions, the relationship between altered RBC biomechanics and thrombosis in the setting of cancer has not been thoroughly investigated. Accordingly, this review synthesizes the mechanistic and clinical data linking altered RBC biomechanics to thrombus initiation, propagation, and stability, with particular emphasis on their relationship with established cancer-related prothrombotic pathways such as extracellular vesicle release, neutrophil extracellular trap formation, stasis, and oxidative stress. Finally, we critically assess current CAT risk assessment models (RAMs) and discuss the potential role of RBC biomechanical parameters as dynamic, integrative biomarkers to improve thrombosis risk stratification in cancer patients. Advances in automated and standardized rheological technologies may facilitate the clinical translation of RBC biomechanics, offering new opportunities to refine risk prediction and deepen mechanistic understanding of CAT.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"561-571"},"PeriodicalIF":4.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147932963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}